Search

Displaying results 1211 - 1220 of 5897 in total
  1. Drug

    Golodirsen

    go.drugbank.com/drugs/DB15593
    ApprovedInvestigational

    Often, patients succumb to this condition by age 30 or younger due to cardiac and respiratory complications. … Golodirsen is a morpholino antisense oligomer designed to treat about 8% of patients with Duchenne Muscular Dystrophy (DMD).

  2. Drug

    Polyvinyl alcohol

    go.drugbank.com/drugs/DB11060
    Approved

    Polyvinyl alcohol is found in ophthalmic solutions as a lubricant to prevent irritation or to relieve dryness of the eyes [L2826].

    Products: Polyvinyl Alcohol Eye Drops 1,4 % w/v
  3. Drug

    Indapamide

    go.drugbank.com/drugs/DB00808
    ApprovedInvestigational

    [A204134] When compared to [hydrochlorothiazide] (another commonly prescribed diuretic), indapamide has been shown to be superior at lowering systolic blood pressure, reducing left ventricular mass index … The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension.

    Mixtures: PERINDOPRIL E INDAPAMIDE MYLAN GENERICS, PERINDOPRIL E INDAPAMIDE MYLAN GENERICSProducts: INDAPAMIDE DOC GENERICI, INDAPAMIDE MYLAN GENERICS
  4. Drug

    Idronoxil

    go.drugbank.com/drugs/DB04915
    Investigational

    It belongs to the family of drugs called signal transduction inhibitors.

  5. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.[A252667] … [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.

  6. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    In addition, a significant improvement in lung function was seen, as measured by the volume of air exhaled by patients in one second [L1133]. … the first attack compared to patients receiving placebo [FDA Label, A31579].

  7. Drug

    Butenafine

    go.drugbank.com/drugs/DB01091
    Approved

    Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols. … In particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes.

  8. Drug

    Glecaprevir

    go.drugbank.com/drugs/DB13879
    ApprovedInvestigational

    patients with moderate to severe kidney disease and those who are on dialysis [L940]. … In combination with [DB13878], glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors.

  9. Drug

    Pantoprazole

    go.drugbank.com/drugs/DB00213
    ApprovedInvestigational

    As the binding of pantoprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, pantoprazole's duration of antisecretory effect persists … This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus.

    Products: PANTOPRAZOL HEXAL 20MG DO, PANTOPRAZOL HEXAL 40MG DO
  10. Drug

    Zimelidine

    go.drugbank.com/drugs/DB04832
    ApprovedWithdrawn

    Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving … Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome